154 related articles for article (PubMed ID: 20642369)
1. Strategies for managing cytomegalovirus in transplant recipients.
Razonable RR
Expert Opin Pharmacother; 2010 Aug; 11(12):1983-97. PubMed ID: 20642369
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
Fisher RA
Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
4. Delayed onset CMV disease in solid organ transplant recipients.
Husain S; Pietrangeli CE; Zeevi A
Transpl Immunol; 2009 May; 21(1):1-9. PubMed ID: 19162183
[TBL] [Abstract][Full Text] [Related]
5. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.
Kotton CN; Kumar D; Caliendo AM; Asberg A; Chou S; Snydman DR; Allen U; Humar A;
Transplantation; 2010 Apr; 89(7):779-95. PubMed ID: 20224515
[TBL] [Abstract][Full Text] [Related]
6. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
7. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD
Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the effects of CMV on long-term transplant outcome.
Baron C; Forconi C; Lebranchu Y
Curr Opin Organ Transplant; 2010 Aug; 15(4):492-8. PubMed ID: 20631617
[TBL] [Abstract][Full Text] [Related]
9. Influence of cytomegalovirus disease in outcome of solid organ transplant patients.
Linares L; Sanclemente G; Cervera C; Hoyo I; Cofán F; Ricart MJ; Pérez-Villa F; Navasa M; Marcos MA; Antón A; Pumarola T; Moreno A
Transplant Proc; 2011; 43(6):2145-8. PubMed ID: 21839217
[TBL] [Abstract][Full Text] [Related]
10. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
Legendre C; Pascual M
Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
12. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
13. Indirect effects of CMV in the solid organ transplant patient.
Paya CV
Transpl Infect Dis; 1999; 1 Suppl 1():8-12. PubMed ID: 11565588
[TBL] [Abstract][Full Text] [Related]
14. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients.
Singh N
Clin Infect Dis; 2008 Jul; 47(2):296-7; author reply 297. PubMed ID: 18564941
[No Abstract] [Full Text] [Related]
15. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.
Le Page AK; Jager MM; Iwasenko JM; Scott GM; Alain S; Rawlinson WD
Clin Infect Dis; 2013 Apr; 56(7):1018-29. PubMed ID: 23243176
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation.
Blyth D; Lee I; Sims KD; Gasink LB; Barton TD; Van Deerlin VM; Pfeiffenberger P; Blumberg EA
Transpl Infect Dis; 2012 Apr; 14(2):149-55. PubMed ID: 22260410
[TBL] [Abstract][Full Text] [Related]
17. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
Stratta RJ; Pietrangeli C; Baillie GM
Pharmacotherapy; 2010 Feb; 30(2):144-57. PubMed ID: 20099989
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cytomegalovirus disease.
Bailey TC
Semin Respir Infect; 1993 Sep; 8(3):225-32. PubMed ID: 8016483
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus infections in transplant patients.
Ljungman P
Scand J Infect Dis Suppl; 1996; 100():59-63. PubMed ID: 8860355
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.
Steininger C
Clin Microbiol Infect; 2007 Oct; 13(10):953-63. PubMed ID: 17803749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
